Embolic Coils and Liquid Embolics Patents: Leaders & Filing Trends 2026
Embolic Coils and Liquid Embolics Patents: Who Leads and Where Filing Is Heading
Concentrated at the top. the five leading assignees hold 43.1% of all 2,981 records in scope, and the leading ten hold 56.3%. Annual filings ran from 96 in 2017 to a peak of 213 in 2020, then fell across the last complete comparison window — 138 in 2021 down to 40 in 2024, a 71% drop. Counts for 2025 and 2026 (8 filings so far) are still incomplete because publication typically lags filing by roughly 18 months, so the tail should not be read as the end of activity, only as data still arriving.
- 1MICROVENTION INC487
- 2COVIDIEN LP318
- 3DEPUY SYNTHES PROD INC285
- 4STRYKER CORP104
- 5BOSTON SCI LTD91
See the full embolic coils and liquid embolics analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on embolic coil and liquid embolic patents
Who holds the most patents on embolic coils and liquid embolics?
The dataset’s assignee ranking shows a single leading filer with 487 records, well ahead of the next-largest holders. The top five assignees combined hold 43.1% of all 2,981 records in scope, and the top ten hold 56.3%. Below the leader, the gap narrows considerably — fifth place holds 91 records and tenth place 69 — meaning competitive positioning is closer in the middle of the ranked field than at the very top.
Is embolic coil and liquid embolic patent filing still growing?
No — filing peaked in 2020 at 213 records and has declined since. Comparing the last two complete years available, filings fell from 138 in 2021 to 40 in 2024, a 71% drop. Figures for 2025 and 2026 look lower still, but that is expected: publication typically lags filing by around 18 months, so the most recent years are undercounted and should not be read as the true end of activity.
What technology areas dominate embolic coil patent claims?
A61B, the diagnosis-and-surgery classification, appears in 72.1% of the 2,981 records in scope, making it by far the largest single category. A61F implants and prostheses follows at 31.9%, and A61M devices for body fluids at 20.9%. Because records can carry multiple IPC classes, these shares add up to more than 100%, but the pattern is clear: delivery and procedural mechanics are far more heavily claimed than the embolic material chemistry itself, which sits in smaller classes like A61K (10.0%) and C08L (1.7%).
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Embolic Coils and Liquid Embolics covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.